Thiotepa Rx

Select the drug indication to add to your list

Thiotepa

Bladder, kidney, and other urologic cancers
Breast cancer
Gynecologic cancers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Thiotepa 15mg; per vial; lyophilized pwd for IV, intravesical, or intracavitary administration after reconstitution.

Select therapeutic use:

Indications for Thiotepa:

Superficial papillary carcinoma of the urinary bladder. Intracavitary effusion due to neoplasm of serosal cavities.

Adult:

Avoid fluids 8–12 hrs prior to treatment. 60mg once weekly for 4 weeks; may repeat up to a total of 3 courses. Retain in bladder for 2 hours. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.

Children:

Not recommended.

Contraindications:

Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.

Warnings/Precautions:

Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.

Note:

Formerly known under the brand name Thioplex.

How Supplied:

Contact supplier.

Indications for Thiotepa:

Adenocarcinomas of the breast. Intracavitary effusion due to neoplasm of serosal cavities.

Adult:

0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.

Children:

Not recommended.

Contraindications:

Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.

Warnings/Precautions:

Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.

Note:

Formerly known under the brand name Thioplex.

How Supplied:

Contact supplier.

Indications for Thiotepa:

Adenocarcinomas of the ovary. Intracavitary effusion due to neoplasm of serosal cavities.

Adult:

0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.

Children:

Not recommended.

Contraindications:

Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.

Warnings/Precautions:

Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.

Note:

Formerly known under the brand name Thioplex.

How Supplied:

Contact supplier.